ArticleClinical pharmacology in drug development2019

An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.